Health Policy News
Michael McFaul, a Stanford political scientist and former U.S. ambassador to Russia, has been selected as the next director of the university’s Freeman Spogli Institute for International Studies.
The announcement was made Wednesday by Stanford Provost John Etchemendy and Ann Arvin, the university’s vice provost and dean of research. McFaul will succeed Mariano-Florentino Cuéllar, who was nominated in July as an associate justice of the California Supreme Court and elected Tuesday.
McFaul takes the helm of FSI in January.
Despite its $7,000-per-week cost, sofosbuvir provides better value than other current treatments for prisoners with hepatitis C, according to Stanford researchers.
New, significantly improved hepatitis C drugs have revolutionized how the disease is treated, but they are also expensive. One such drug, sofosbuvir, costs more than $7,000 a week for 12 weeks of treatment.
Traditional drug repurposing, although successful in treating some diseases, still requires considerable time to identify candidate compounds and even more time to test them in clinical trials. Ebola requires and deserves a much more aggressive approach, while still balancing safety and efficacy concerns.